IFNA1 and sarcoidosis: The IFN+ and IFN- signatures were assessed on the test MDS and validated on two independent datasets, one including healthy controls and TB patients from China (15) and one including healthy controls as well as TB and sarcoidosis patients from an ethnically diverse population in London (47).